 SEATTLE, June 08, 2021 GLOBE NEWSWIRE -- Chinook Therapeutics, Inc. Nasdaq: KDNY, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the presentation of data from the ongoing phase 12 study of BION-1301 in patients with IgAN. The findings were presented in an oral presentation at the 58th European Renal Association European Dialysis and Transplant Association ERA-EDTA Virtual Congress. 